Cardiac iPSCs for Disease Modeling and Drug Discovery
Director of the Stanford Cardiovascular Institute and Professor in the Department of Medicine (Cardiology) and Department of Radiology
Stanford Cardiovascular Institute, Stanford University
April 30, 2015
Foege N130A, Wallace H. Coulter Seminar Room
Cardiac toxicity is a side effect of many pharmaceutical compounds and is a leading cause for drug withdrawal from market because of safety concerns. Current preclinical methods to measure cardiotoxicity are inefficient and rely on genetically altered cell lines, which do not accurately resemble human heart cells. Recent technological advancement has enabled the generation of patient-specific human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in vitro. The iPSC-CMs generated in this fashion carry all the genetic information from the individuals from whom they are derived. Here I will discuss the generation of iPSC-CMs from patients with cardiovascular diseases. I will give examples showing how iPSC-CMs can detect drug-induced cardiac toxicity more accurately than the conventional hERG testing used by most pharmaceutical companies. I will also discuss the potential applications of iPSC-CMs for disease modeling and regenerative medicine applications.
Joseph C. Wu, MD, PhD, is currently Director of the Stanford Cardiovascular Institute and Professor in the Department of Medicine (Cardiology) and Department of Radiology at the Stanford School of Medicine. Dr. Wu received his M.D. from Yale University School of Medicine. He completed his cardiology fellowship training followed by a PhD in Molecular Pharmacology at UCLA. Dr. Wu has received numerous prestigious awards, including the Burroughs Wellcome Foundation Career Award for Medical Scientists (2007), the NIH Director’s New Innovator Award (2008), the Baxter Foundation Faculty Award (2008), the NIH Roadmap Transformative Award (2009), the AHA National Innovative Research Award (2009), the Presidential Early Career Award for Scientists and Engineers given by President Obama (2010), and the AHA Established Investigator Award (2013). Dr. Wu is a member of the Association of University Cardiologist (AUC), Association of American Physician (AAP), a Council member for the American Society of Clinical Investigation (ASCI), and a Scientific Advisory Board member for the Keystone Symposia. Dr. Wu serves on the Editorial Board of Journal Clinical Investigation, Circulation Research, Circulation Cardiov Imaging, JACC Cardiov Imaging, Human Gene Therapy, Molecular Therapy, Journal of Nuclear Cardiology, and Stem Cell Research. Dr. Wu has published >220 manuscripts. His lab uses a combination of genomics, cellular & molecular biology, physiological testing, and molecular imaging technologies to better understand molecular and pathophysiological processes. The lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are for (i) understanding cardiovascular disease mechanism, (ii) accelerate drug discovery and screening, and (iii) develop personalized medicine platforms.